Spironolakton – żwawy 56-latek do wzięcia, na razie wcale nie myśli jeszcze o emeryturze... Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2013
Słowa kluczowe:
spironolakton, aldosteron, antagoniści receptora mineralokortykoidowego, nadciśnienie tętnicze, niewydolność serca, choroby układu krążenia
##plugins.themes.bootstrap3.article.main##
Abstrakt
Antagoniści receptora mineralokortykoidowego znajdują coraz większe zastosowanie w leczeniu pacjentów z chorobami układu sercowo-naczyniowego, zwłaszcza z nadciśnieniem tętniczym, pierwotnym hiperaldosteronizmem oraz niewydolnością serca. W randomizowanych, kontrolowanych próbach klinicznych wykazano, że leki z tej grupy zmniejszają umieralność i chorobowość pacjentów ze skurczową niewydolnością serca. W niniejszej pracy omówiono pierwszy lek z tej grupy, spironolakton, oraz podsumowano dowody odnoszące się do jego stosowania u pacjentów z nadciśnieniem tętniczym, pierwotnym hiperaldosteronizmem oraz niewydolnością serca, zwłaszcza w kontekście porównania pod względem przydatności spironolaktonu z jego konkurentem, eplerenonem.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Jędrusik , P. (2013). Spironolakton – żwawy 56-latek do wzięcia, na razie wcale nie myśli jeszcze o emeryturze. . Medycyna Faktów , 6(3(20), 38-47. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2405
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Nagarajan V., Chamsi-Pasha M., Tang W.H.W.: The role of aldosterone receptor antagonists in the management of heart failure: An update. Cleve. Clin. J. Med. 2012; 79: 631-639.
2. Struthers A., Krum H., Williams G.H.: A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin. Cardiol. 2008; 31: 153-158.
3. Maron B.A., Leopold J.A.: Aldosterone antagonists: effective but often forgotten. Circulation 2010; 121: 934-939.
4. Nishizaka M.K., Zaman M.A., Calhoun D.A.: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am. J. Hypertens. 2003; 16: 925-930.
5. Jeunemaitre X., Chatellier G., Kreft-Jais C. et al.: Efficacy and tolerance of spironolactone in essential hypertension. Am. J. Cardiol. 1987; 60: 820-825.
6. Juurlink D.N., Mamdani M.M., Lee D.S. et al.: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 2004; 351: 543-551.
7. Vasan R.S., Evans J.C., Larson M.G. et al.: Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N. Engl. J. Med. 2004; 351: 33-41.
8. Bednarz B.: Spironolakton. W: Główne leki kardiologiczne – Tom I. Biblioteka Kardiologii Polskiej. Warszawa 1997.
9. Henry M., Wehrlen M., Pelletier B. et al.: Spironolactone versus nifedipine in essential hypertension. Am. J. Cardiol. 1990; 65: 36K-38K.
10. Plouin P.F., Battaglia C., Alhenc-Gélas F. et al.: Are angiotensin converting enzyme inhibition and aldosterone antagonism equivalent in hypertensive patients over fifty? Am. J. Hypertens. 1991; 4: 356-362.
11. Catena C., Colussi G., Lapenna R. et al.: Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911-918.
12. Gaddam K., Pimenta E., Thomas S.J. et al.: Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J. Hum. Hypertens. 2010; 24: 532-537.
13. Chapman N., Dobson J., Wilson S. et al.: Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 1-7.
14. Vaclavik J., Sedlak R., Plachy M. et al.: Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57: 1069-1075.
15. Pitt B., Zannad F., Remme W.J. et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 1999; 341: 709-717.
16. Hamaguchi S., Kinugawa S., Tsuchihashi-Makaya M. et al.: Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. Am. Heart J. 2010; 160: 1156-62.
17. Hayashi M., Tsutamoto T., Wada A. et al.: Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents postinfarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003; 107: 2559-2565.
18. Pitt B., Remme W., Zannad F. et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003; 348: 1309-1321.
19. Zannad F., McMurray J.J.V., Krum H. et al.: Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011; 364: 11-21.
20. McMurray J.J.V., Adamopoulos S., Anker S.D. et al.: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur. Heart J. 2012; 33: 1787-1847.
21. Yancy C.W., Jessup M., Bozkurt B. et al.: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013 [online: doi: 10.1161/ CIR.0b013e31829e8776].
22. Edelmann F., Schmidt A.G., Gelbrich G. et al.: Rationale and design of the ‘aldosterone receptor blockade in diastolic heart failure’ trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). Eur. J. Heart Fail. 2010; 12: 874-882.
23. Bianchi S., Bigazzi R., Campese V.M.: Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006; 70: 2116-2123.
24. Schjoedt K.J., Rossing K., Juhl T.R. et al.: Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006; 70: 536-542.
25. Navaneethan S.D., Nigwekar S.U., Sehgal A.R. et al.: Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 2009; 4: 542-551.
26. Shibata H., Itoh H.: Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am. J. Hypertens. 2012; 25: 514-523.
27. Parthasarathy K.H., Menard J., White W.B.: A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J. Hypertens. 2011; 29: 980-990.
28. Weinberger M.H., Roniker B., Krause S.L. et al.: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. 2002; 15: 709-716.
29. Unger T., Paulis L., Sica D.A.: Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur. Heart J. 2011; 32: 2739-2747.
30. Chatterjee S., Moeller C., Shah N. et al.: Eplerenone is not superior to older and less expensive aldosterone antagonists. Am. J. Med. 2012; 125: 817-825.
2. Struthers A., Krum H., Williams G.H.: A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin. Cardiol. 2008; 31: 153-158.
3. Maron B.A., Leopold J.A.: Aldosterone antagonists: effective but often forgotten. Circulation 2010; 121: 934-939.
4. Nishizaka M.K., Zaman M.A., Calhoun D.A.: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am. J. Hypertens. 2003; 16: 925-930.
5. Jeunemaitre X., Chatellier G., Kreft-Jais C. et al.: Efficacy and tolerance of spironolactone in essential hypertension. Am. J. Cardiol. 1987; 60: 820-825.
6. Juurlink D.N., Mamdani M.M., Lee D.S. et al.: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 2004; 351: 543-551.
7. Vasan R.S., Evans J.C., Larson M.G. et al.: Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N. Engl. J. Med. 2004; 351: 33-41.
8. Bednarz B.: Spironolakton. W: Główne leki kardiologiczne – Tom I. Biblioteka Kardiologii Polskiej. Warszawa 1997.
9. Henry M., Wehrlen M., Pelletier B. et al.: Spironolactone versus nifedipine in essential hypertension. Am. J. Cardiol. 1990; 65: 36K-38K.
10. Plouin P.F., Battaglia C., Alhenc-Gélas F. et al.: Are angiotensin converting enzyme inhibition and aldosterone antagonism equivalent in hypertensive patients over fifty? Am. J. Hypertens. 1991; 4: 356-362.
11. Catena C., Colussi G., Lapenna R. et al.: Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911-918.
12. Gaddam K., Pimenta E., Thomas S.J. et al.: Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J. Hum. Hypertens. 2010; 24: 532-537.
13. Chapman N., Dobson J., Wilson S. et al.: Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 1-7.
14. Vaclavik J., Sedlak R., Plachy M. et al.: Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57: 1069-1075.
15. Pitt B., Zannad F., Remme W.J. et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 1999; 341: 709-717.
16. Hamaguchi S., Kinugawa S., Tsuchihashi-Makaya M. et al.: Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. Am. Heart J. 2010; 160: 1156-62.
17. Hayashi M., Tsutamoto T., Wada A. et al.: Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents postinfarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003; 107: 2559-2565.
18. Pitt B., Remme W., Zannad F. et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003; 348: 1309-1321.
19. Zannad F., McMurray J.J.V., Krum H. et al.: Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011; 364: 11-21.
20. McMurray J.J.V., Adamopoulos S., Anker S.D. et al.: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur. Heart J. 2012; 33: 1787-1847.
21. Yancy C.W., Jessup M., Bozkurt B. et al.: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013 [online: doi: 10.1161/ CIR.0b013e31829e8776].
22. Edelmann F., Schmidt A.G., Gelbrich G. et al.: Rationale and design of the ‘aldosterone receptor blockade in diastolic heart failure’ trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). Eur. J. Heart Fail. 2010; 12: 874-882.
23. Bianchi S., Bigazzi R., Campese V.M.: Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006; 70: 2116-2123.
24. Schjoedt K.J., Rossing K., Juhl T.R. et al.: Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006; 70: 536-542.
25. Navaneethan S.D., Nigwekar S.U., Sehgal A.R. et al.: Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 2009; 4: 542-551.
26. Shibata H., Itoh H.: Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am. J. Hypertens. 2012; 25: 514-523.
27. Parthasarathy K.H., Menard J., White W.B.: A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J. Hypertens. 2011; 29: 980-990.
28. Weinberger M.H., Roniker B., Krause S.L. et al.: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. 2002; 15: 709-716.
29. Unger T., Paulis L., Sica D.A.: Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur. Heart J. 2011; 32: 2739-2747.
30. Chatterjee S., Moeller C., Shah N. et al.: Eplerenone is not superior to older and less expensive aldosterone antagonists. Am. J. Med. 2012; 125: 817-825.